SGLT2 inhibitors (SGLT2i) are a class of pharmaceuticals that lower blood glucose by causing glucosuria, thereby inhibiting glucose reabsorption from glomerular filtration back into circulation.2,3 In addition, SGLT2i have been shown to provide significant cardiovascular and renal protection in patients with and without diabetes.4 In 2013, canagliflozin was the first SGLT2i approved by the United States (US) Food and Drug Administration (FDA) for the treatment of type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.